Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1994-2-15
|
pubmed:abstractText |
Patients whose lymphoma is resistant to standard treatment regimens continue to do poorly, with only an occasional patient achieving long-term remission even with bone marrow transplantation. Twenty-three patients with primarily refractory (11), or refractory relapsed (12) non-Hodgkin's lymphoma were treated with repeated cycles of dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) without bone marrow transplantation. Each cycle of DICEP consisted of cyclophosphamide (2500 mg/m2/day, days 1-2), etoposide (500 mg/m2/day, days 1-3), and cisplatin (50 mg/m2/day, days 1-3). Twelve patients (52%) have achieved a complete response and 6 (26%)r a partial response. Three of the complete responders remain continuously free of disease for 19, 29, and 32 months, and 3 more are disease-free at 58, 59, and 65 months after receiving further therapy. Three-year survival for all patients is 45%. Patients with a good initial performance status (Zubrod 0 or 1) had a 58% complete response rate and a 2-year survival rate of 53%. One of 19 patients with an initial performance status of 0 or 1 had treatment-related mortality. Repeated cycles of DICEP can produce long-term responses in patients with refractory non-Hodgkin's lymphoma.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0735-7907
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
12
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1-11
|
pubmed:dateRevised |
2006-4-24
|
pubmed:meshHeading |
pubmed-meshheading:8281458-Adult,
pubmed-meshheading:8281458-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8281458-Cisplatin,
pubmed-meshheading:8281458-Cyclophosphamide,
pubmed-meshheading:8281458-Drug Resistance,
pubmed-meshheading:8281458-Etoposide,
pubmed-meshheading:8281458-Female,
pubmed-meshheading:8281458-Follow-Up Studies,
pubmed-meshheading:8281458-Humans,
pubmed-meshheading:8281458-Lymphoma, Non-Hodgkin,
pubmed-meshheading:8281458-Male,
pubmed-meshheading:8281458-Middle Aged,
pubmed-meshheading:8281458-Neoplasm Recurrence, Local,
pubmed-meshheading:8281458-Survival Rate,
pubmed-meshheading:8281458-Treatment Outcome
|
pubmed:year |
1994
|
pubmed:articleTitle |
Multiple cycles of dose-intensive cyclophosphamide, etoposide, and cisplatinum (DICEP) produce durable responses in refractory non-Hodgkin's lymphoma.
|
pubmed:affiliation |
University of New Mexico Cancer Center, Albuquerque 87131.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|